HeartSciences Inc. is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. The Company has libraries of artificial intelligence-enhanced electrocardiography (AI-ECG) algorithms and is developing AI-ECG solutions to be made available on either a hardware- agnostic cloud-based platform or its proprietary MyoVista wavECG device, to help identify cardiovascular disease in any care setting worldwide in a manner to suit different care providers. Its first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction, which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test. It delivers AI-ECG algorithms using existing ECG devices across a hospital or health system.
公司代碼HSCS
公司名稱HeartSciences Inc
上市日期Jun 15, 2022
CEOSimpson (Andrew)
員工數量15
證券類型Ordinary Share
年結日Jun 15
公司地址550 Reserve St, Suite 360
城市SOUTHLAKE
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編76092
電話16822377781
網址https://heartsciences.com/
公司代碼HSCS
上市日期Jun 15, 2022
CEOSimpson (Andrew)